Background: Evidence suggests that classical psychedelics can promote enduring changes in personality, attitudes and optimism, as well as improvements in mental health outcomes. Aim: To investigate the effects of a composite intervention, involving psilocybin, on pessimism biases in patients with treatment-resistant depression (TRD). Methods: Patients with TRD (n = 15) and matched, untreated...
The Buddhist construct of nonattachment is a related, yet distinct construct to mindfulness. Whereas mindfulness refers to an individual’s open, present-centred awareness of what is happening in their field of consciousness, nonattachment denotes an absence of attempts to control what is happening in their field of consciousness. The aim of the present research was to determine whether...
Depression is a common mental disorder that is associated with memory dysfunction. Ketamine has recently been demonstrated to be a rapid antidepressant. The mechanisms underlying how depression induces memory dysfunction and how ketamine relieves depressive symptoms remain poorly understood. In this work, we have three groups of male C57BL/6J mice: mice exposed to chronic social defeat stress...
Introduction: Positive social interactions (PSIs) and stable relationships can exert substantial benefits on health. However, patients suffering from depression benefit less from these health-promoting effects. Moreover, relationship quality and even partners' health has been found to be negatively affected by depressive symptomatology, which may result in overall impairments in social...
The aim of the current study was to examine the unique role of mindfulness skills in terms of: (1) asthma-related outcomes (i.e., asthma control, asthma quality of life); (2) depression symptoms; and (3) anxiety symptomatology (i.e., anxiety sensitivity, panic symptoms, global anxiety) among non-smoking adults with current asthma. Participants were 61 (61.9% female; Mage = 34.72 years, SD =...
Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA receptor antagonist, to induce rapid (within hours), transient antidepressant effects when administered intravenously (IV) at subanesthetic doses (0.5 mg/kg over 40 min). However, the optimal antidepressant dose remains unknown. We aimed to compare to active placebo the rapid acting antidepressant properties...
To the Editors: W orldwide, major depressive disorder (MDD) is a leading cause of disability and a major contributor to the overall global burden of disease. Up to 30%of patients with MDD have a lack of response to antidepressant therapies. These rates are even higher in bipolar depression, where treatment options are more limited than in MDD. Patients who do not achieve an adequate...
K anesthesia was introduced about half a century ago. In recent decades, this drug, in subanesthetic doses, has also demonstrated efficacy for off-label indications including treating acute and chronic pain, treating agitation, treating depression, and inducing sedation. Thus, there are studies of subanesthetic dosing with ketamine for treating pain in emergency medicine settings, treating...
Background: Although interest in ketamine use during electroconvulsive therapy (ECT) has increased, studies have been equivocal with regard to its efficacy. The aims of this clinical trial were to evaluate ketamine’s antidepressive effects in ECT as a primary anesthetic, determine ketamine’s tolerability when compared with standard anesthesia, and determine if plasma brain-derived neurotrophic...
The discovery of the antidepressant effects of ketamine has opened a breakthrough opportunity to develop a truly novel class of safe, effective, and rapid-acting antidepressants (RAADs). In addition, the rapid and robust biological and behavioral effects of ketamine offered a unique opportunity to utilize the drug as a tool to thoroughly investigate the neurobiology of stress and depression in...